Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
The Russian Ministry of Health announces achievements in the field of orphan disease care
- By Newsdesk
- Russia
- Apr 04, 2023
Russia is increasing its resources for orphan disease care, including the production of domestic medicines for the treatment of rare diseases, according to Sergey Glagolev, Deputy Minister of Health. During a Federation Council meeting on Monday, April 3, he stated that a domestic manufacturer is currently conducting clinical trials of Russia's first drug for the genetic therapy of spinal muscular atrophy (SMA).
The Russian Federation's Ministry of Health granted Biocad permission for the first and second phases of the trial in 2022. Glagolev did not identify the company, but the statement is most likely about Biocad. Its ANB-4 drug is the first Russian medicine for the treatment of SMA. Preclinical studies were completed successfully, allowing for the determination of an effective and safe dose for the drug's initial administration to patients.
Furthermore, according to the NAFI Analytical Center and the Liudi-Mayaki (People-Beacons) charity foundation, 65% of Russians are unaware of orphan diseases. This was discovered in a survey of 1,100 adults over the age of 18. Only 7% of respondents are aware of the issue of rare diseases, and the diseases most of these people were aware of were SMA (58%), lymphoma (54%), and haemophilia (49%).